Literature DB >> 8142656

Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes.

H Cavé1, C Guidal, P Rohrlich, M H Delfau, A Broyart, B Lescoeur, C Rahimy, O Fenneteau, N Monplaisir, L d'Auriol.   

Abstract

We have developed a strategy based on polymerase chain reaction (PCR) for detecting all possible gamma T-cell receptor (gamma TCR) rearrangements and the most common delta TCR rearrangements found in B-lineage and T-acute lymphoblastic leukemia (T-ALL). The segments amplified from blasts are then directly sequenced to derive clonospecific probes. From a series of 45 patients aged 1 to 15 years (42 B-lineage ALL, 3 T-ALL), 35 (83%) could be followed for minimal residual disease with at least one clonospecific probe. Detection of clonal markers using clonospecific probes routinely allowed the detection of 1 to 10 blasts out of 10(5) cells as determined by serial dilutions of the initial samples. Residual disease was quantitated by a competitive PCR assay based on the coamplification of an internal standard. Twenty children were prospectively followed for periods varying from 7 to 30 months. In most children, a progressive decrease of the tumor load was observed, and blasts became undetectable within 6 months after the initiation of treatment. A slower kinetics of decrease in tumor cells was found in three children. These three patients relapsed with blasts that continued to display the initial clonospecific markers. Three other children had a central nervous system relapse despite the absence of detectable medullary residual disease. The use of both delta and gamma TCR genes as clonal markers, as well as simplification in the methods to detect and quantify residual blasts reported here, will allow the study of the large number of patients required to determine the role of the detection of minimal residual disease by PCR in the follow-up of childhood ALL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142656

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.

Authors:  A Lal; E Kwan; M al Mahr; L Zhou; D Ferrara; V Tobias; D O'Gorman Hughes; M Haber; M D Norris; G M Marshall
Journal:  Mol Pathol       Date:  1998-10

4.  A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.

Authors:  Elaine Coustan-Smith; Raul C Ribeiro; Patricia Stow; Yinmei Zhou; Ching-Hon Pui; Gaston K Rivera; Francisco Pedrosa; Dario Campana
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

5.  Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.

Authors:  C Scholten; M Födinger; M Mitterbauer; K Laczika; G Mitterbauer; O A Haas; P Knöbl; I Schwarzinger; R Thalhammer; B Purtscher
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

6.  Static micro-array isolation, dynamic time series classification, capture and enumeration of spiked breast cancer cells in blood: the nanotube-CTC chip.

Authors:  Farhad Khosravi; Patrick J Trainor; Christopher Lambert; Goetz Kloecker; Eric Wickstrom; Shesh N Rai; Balaji Panchapakesan
Journal:  Nanotechnology       Date:  2016-09-29       Impact factor: 3.874

Review 7.  The molecular detection of circulating tumour cells.

Authors:  P W Johnson; S A Burchill; P J Selby
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

8.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.